Cyclacel Pharmaceuticals (CYCC) soars 35% before the bell.
A poster presentation from AACR shows the active metabolite of sapacitabine was active against three quarters of isolated primary ovarian cancer samples.
By contrast, the chemotherapy drug cisplatin was active in "less than half" of the samples.
More than half of the platinum-resistant samples were sensitive to sapacitabine. (PR)
Janney initiated the shares at Buy earlier this month.
For more, see a recent article by SA contributor Scrying Biotech who said on September 7 that "with or without you, Cyclacel is going to rise."